Patent Term Extension Application for BRIUMVI® (ublituximab-xiiy), Patent No. 9,873,745
🏛 Food and Drug Administration (FDA)FDA-2023-E-3264
Documents
0
Total comments
0
all analyzed
Comment status
Closed
Last activity
—
In this docket
Documents
Rules, notices, and supporting material — the primary rule pinned first.
No documents mirrored for this docket yet.